Lexaria Bioscience Corp.
No SEC Form 4 filings for $LEXX in the last 30 days.
See all $LEXX insider activity →Lexaria Bioscience (LEXX) signed a Material Transfer Agreement with PegBio to test Lexaria’s DehydraTECH drug delivery platform using PegBio’s proprietary GLP-1 molecule for animal studies. The goal is to assess pharmacokinetics and explore oral delivery for diabetes, obesity, and metabolic diseases. LEXX trades at $7.68, up 25.54%, after a 1-for-15 reverse split on Aug 3, 2026.
Lexaria Bioscience (NASDAQ:LEXX) said it signed a material transfer agreement with Pegbio Co., Ltd. to test Lexaria’s DehydraTECH drug-delivery technology using a proprietary Pegbio GLP-1 molecule for GLP-1 industry applications. Pegbio will supply the molecule for animal pharmacokinetic studies. Lexaria plans to update after study completion.
Lexaria Bioscience Corp. (Nasdaq: LEXX) said its reverse stock split will take effect at 12:01 a.m. ET on Aug. 3, 2026, on a 1-for-15 basis, to help regain Nasdaq compliance with the $1.00 minimum bid rule. Shares will trade under LEXX with a new CUSIP. Authorized shares and convertible securities will be adjusted.
Over the past 7 days, alphai's AI scored 2 news stories mentioning LEXX (Lexaria Bioscience Corp.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent LEXX coverage spans technology, financial news and corporate actions.
The PegBio collaboration is a concrete platform validation step that could improve Lexaria’s oral GLP-1 positioning, but it is preclinical and lacks quantified results.
The MTA is a new partnering step that can support future licensing or commercialization, but it is not yet a revenue event.
The scheduled reverse split is a near-term corporate action that can mechanically move the stock price and affect liquidity, while the stated goal is Nasdaq compliance.
Conference-driven business development update suggests expanding partner interest, but provides no deal terms or timeline.
Fresh preclinical dosing milestone and an additional patent grant support Lexaria’s GLP-1 oral delivery IP narrative, but no efficacy data are provided yet.
alphai scores every news story that mentions LEXX with an AI model for sentiment and relevance, and aggregates insider trades from Lexaria Bioscience Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lexaria Bioscience (LEXX) signed a Material Transfer Agreement with PegBio to test Lexaria’s DehydraTECH drug delivery platform using PegBio’s proprietary GLP-1 molecule for animal studies. The goal is to assess pharmacokinetics and explore oral delivery for diabetes, obesity, and metabolic diseases. LEXX trades at $7.68, up 25.54%, after a 1-for-15 reverse split on Aug 3, 2026.
3 min readLexaria Bioscience (NASDAQ:LEXX) said it signed a material transfer agreement with Pegbio Co., Ltd. to test Lexaria’s DehydraTECH drug-delivery technology using a proprietary Pegbio GLP-1 molecule for GLP-1 industry applications. Pegbio will supply the molecule for animal pharmacokinetic studies. Lexaria plans to update after study completion.
2 min readLexaria Bioscience Corp. (Nasdaq: LEXX) said its reverse stock split will take effect at 12:01 a.m. ET on Aug. 3, 2026, on a 1-for-15 basis, to help regain Nasdaq compliance with the $1.00 minimum bid rule. Shares will trade under LEXX with a new CUSIP. Authorized shares and convertible securities will be adjusted.
3 min readLexaria Bioscience Corp. (NASDAQ:LEXX) said it held multiple meetings with potential pharma partners at the 2026 BIO International Convention in San Diego, aiming to form partnership arrangements. The company cited increased GLP-1 discussions focused on drug safety and adverse-event profiles, and renewed interest in its DehydraTECH-CBD and DehydraTECH-nicotine programs.
2 min readLexaria Bioscience (NASDAQ: LEXX) said animal Study GLP-1-A26-1 began dosing on June 10, 2026, on schedule, using Sprague-Dawley rats to test DehydraTECH-semaglutide and DehydraTECH-CBD formulations. Results are expected in early September. The company also reported an Australian patent grant (No. 2023302884) granted June 11, 2026, valid until April 25, 2043.
3 min readLexaria Bioscience Corp. is advancing its Human Pilot Study #7 (GLP-1-H26-7) to evaluate two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets. The company has completed laboratory work and manufacturing of test articles, and is awaiting ethics approval and final quality control. This study introduces new DehydraTECH enhancements, including an oral tablet form and the use of SNAC in multi-dose, multi-week human trials, aiming for improved safety, tolerability, and pharmacokinetic performance to potentially attract commercial pharmaceutical partnerships.
4 min readLexaria Bioscience Corp. ( NASDAQ: LEXX ) experienced a dramatic 45.10% surge in after-hours trading on Thursday, climbing to $2.22 from its closing price of $1.53. According to Benzinga Pro data, the biotech company's regular trading session had already shown strength with a 7.75% gain.
3 min read
